Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable/Metastatic Melanoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT01433991
What this trial is testing

E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)

Who this might be right for
Advanced Solid Tumors
Eisai Inc. 30
Large-scale testing (Phase 3)Study completedNCT03430297
What this trial is testing

A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma

Who this might be right for
Metastatic MelanomaUnresectable Melanoma
Shanghai Junshi Bioscience Co., Ltd. 256
Testing effectiveness (Phase 2)Active Not RecruitingNCT06784648
What this trial is testing

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

Who this might be right for
Melanoma MetastaticMelanoma of SkinMelanoma BRAF V600E/K Mutated+7 more
BioInvent International AB 35
Early research (Phase 1)Study completedNCT01621490
What this trial is testing

PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma

Who this might be right for
Advanced MelanomaMetastatic Melanoma
Bristol-Myers Squibb 170
Not applicableNo Longer AvailableNCT02142218
What this trial is testing

Expanded Access Program With Nivolumab to Treat Melanoma

Who this might be right for
Stage III (Unresectable) or Stage IV Advanced Melanoma
Bristol-Myers Squibb
Large-scale testing (Phase 3)Active Not RecruitingNCT04657991
What this trial is testing

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

Who this might be right for
Melanoma
Pfizer 257
Testing effectiveness (Phase 2)Active Not RecruitingNCT04940299
What this trial is testing

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Who this might be right for
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced Bladder Carcinoma+39 more
M.D. Anderson Cancer Center 35
Large-scale testing (Phase 3)Active Not RecruitingNCT02224781
What this trial is testing

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Who this might be right for
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Melanoma+2 more
National Cancer Institute (NCI) 267
Early research (Phase 1)Active Not RecruitingNCT06377111
What this trial is testing

Test the Benefit of Vitamin B5 in Patients With Melanoma

Who this might be right for
Melanoma (Skin)
University Health Network, Toronto 12
Large-scale testing (Phase 3)Active Not RecruitingNCT05625399
What this trial is testing

Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

Who this might be right for
Melanoma
Bristol-Myers Squibb 579
Not applicableNo Longer AvailableNCT02416232
What this trial is testing

Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

Who this might be right for
Melanoma
GlaxoSmithKline
Testing effectiveness (Phase 2)Looking for participantsNCT07280832
What this trial is testing

Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors

Who this might be right for
Unresectable Locally Advanced or Metastatic MelanomaUnresectable Locally Advanced or Metastatic Urinary Tract Tumors
Shanghai JMT-Bio Inc. 500
Testing effectiveness (Phase 2)Study completedNCT00189332
What this trial is testing

Use of 852A in Metastatic Cutaneous Melanoma.

Who this might be right for
MelanomaUnresectable Metatstatic Cutaneous Melanoma
Pfizer 28
Early research (Phase 1)Study completedNCT03538314
What this trial is testing

UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Ultimovacs ASA 30
Large-scale testing (Phase 3)Active Not RecruitingNCT05352672
What this trial is testing

Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

Who this might be right for
Melanoma
Regeneron Pharmaceuticals 1,546
Early research (Phase 1)Study completedNCT02595866
What this trial is testing

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

Who this might be right for
AIDS-Related Non-Hodgkin LymphomaClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+16 more
National Cancer Institute (NCI) 58
Early research (Phase 1)Study completedNCT03864042
What this trial is testing

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsMetastatic Melanoma
Pfizer 56
Testing effectiveness (Phase 2)Active Not RecruitingNCT01989585
What this trial is testing

Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

Who this might be right for
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Malignant Solid Neoplasm+2 more
National Cancer Institute (NCI) 75
Early research (Phase 1)Active Not RecruitingNCT01364051
What this trial is testing

Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies

Who this might be right for
Metastatic MelanomaRefractory Malignant Solid NeoplasmStage IV Cutaneous Melanoma AJCC v6 and v7+1 more
National Cancer Institute (NCI) 19
Early research (Phase 1)Ended earlyNCT01783431
What this trial is testing

Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells

Who this might be right for
Melanoma
Medical University of South Carolina 1
Next Page